**Supplementary Table 3. Characteristics of** **citations on IR and BE risk**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Year** | **Country** | **Study design** | **Sample size** | **Male / Female** | **Mean age** | **Insulin** | **HOMA-IR (SD)** |
| [Caro et al.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Matthews%20DR%5bAuthor%5d&cauthor=true&cauthor_uid=3899825)  | 2015 | UK | case-control | 474 | 285 / 189 | 58.08 (15.51) | 10.20 | 2.54 ( 2.66) |
| Greer et al.  | 2012 | US | case-control | 1,067 | 431 / 636 | 63.70 (11.20) | 10.20 | 2.78 (2.61) |
| Hsu et al.  | 2011 | Taiwan | case-control | 743 | 343 / 400 | 51.30 (11.00) | NA | 2.10 (2.70) |
| Ryan et al.  | 2008 | Ireland | cohort | 102 | 70 / 32 | 59.00 (12.00) | 7.50 | 2.50 (2.90) |
| Winzer et al.  | 2015 | Australia | cohort | 33 | 33 / 0 | 57.20 (7.50) | NA | 2.20 (1.10) |
| Arcidiacono et al. | 2017 | Italy | cohort | 108 | 87 / 21 | 54.30 (11.20) | 251.30 | 1.40 (1.82) |
| Chak et al.  | 2015 | US | cohort | 74 | 58 / 16 | 59.20 (11.00) | 11.40 | 2.70 (1.80) |
| Duggan et al.  | 2013 | US | cohort | 392 | 321 / 71 | 61.00 (11.50) | 98.80 | 2.36 (1.62) |
| Park et al.  | 2008 | South Korea | case-control | 5,037 | 3,425 / 1,612 | 45.20 (9.70) | 98.40 | 2.41 (1.10) |

BE: Barrett’s esophagus; HOMA-IR: Homeostasis Model of Assessment for Insulin Resistance; IR: insulin resistance; SD: standard deviation; NA: not available.